Published in J Immunother Cancer on February 16, 2016
Sudden hearing loss in a melanoma patient on pembrolizumab: an etiology not to be omitted in the differential diagnosis. J Immunother Cancer (2017) 0.75
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol (2012) 5.23
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol (2013) 1.90
Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab (2013) 1.42
Vogt-Koyanagi-Harada syndrome. Autoimmun Rev (2013) 1.35
Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1. Front Immunol (2014) 1.18
The use of endogenous T cells for adoptive transfer. Immunol Rev (2014) 1.10
Melanocytes and their diseases. Cold Spring Harb Perspect Med (2014) 0.97
Audiovestibular dysfunction associated with adoptive cell immunotherapy for melanoma. Otolaryngol Head Neck Surg (2012) 0.94
Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) (2014) 0.92